1,253 reports of this reaction
5.5% of all FREMANEZUMAB VFRM reports
#2 most reported adverse reaction
INJECTION SITE PAIN is the #2 most commonly reported adverse reaction for FREMANEZUMAB VFRM, manufactured by Teva Pharmaceuticals USA, Inc.. There are 1,253 FDA adverse event reports linking FREMANEZUMAB VFRM to INJECTION SITE PAIN. This represents approximately 5.5% of all 22,887 adverse event reports for this drug.
Patients taking FREMANEZUMAB VFRM who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is moderately reported among FREMANEZUMAB VFRM users, representing a notable but not dominant share of adverse events.
In addition to injection site pain, the following adverse reactions have been reported for FREMANEZUMAB VFRM:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 1,253 FDA reports for FREMANEZUMAB VFRM. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 5.5% of all adverse event reports for FREMANEZUMAB VFRM, making it one of the most commonly reported side effect.
If you experience injection site pain while taking FREMANEZUMAB VFRM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.